Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 08-03 19:04:43时区推断·⟳ 抓取 08-03 19:05:49·⚡ 决策 08-04 03:39:54 +8h34m·84.7 天前
再鼎医药Zoci获FDA神经内分泌癌孤儿药资格认定
FDA孤儿药资格认定可带来费用减免、税收抵免和获批后的潜在七年市场独占期，但它不是上市批准，也不直接产生收入。
📄 原文Investing.com↗ 原文
Zai Lab’s zoci receives FDA orphan drug designation for NECs
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks SHANGHAI & CAMBRIDGE, Mass. - Zai Lab Limited (…
不做 再鼎医药（09688.HK）
FDA孤儿药资格是研发激励而非上市批准或销售放量，且Zoci相关监管进展已有连续传播，短期收入量级不可量化。
不做 Zai Lab（ZLAB.US）
同一管线消息对美股ADS也缺少即时商业化收入和获批节点，不追研发资格类软催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 媒体称再鼎医药Zoci获FDA用于神经内分泌癌的孤儿药资格认定，并计划2026年底前开展三项注册性研究。
- 公司此前已披露Zoci获EMA孤儿药资格，且提到此前已获FDA epNEC快速通道资格，说明同一管线监管催化已有连续传播。
- 公司管线页显示Zoci早在2025年1月已获FDA孤儿药资格并处于小细胞肺癌关键III期，当前不是首次验证该资产。
关键理由
- FDA孤儿药资格认定可带来费用减免、税收抵免和获批后的潜在七年市场独占期，但它不是上市批准，也不直接产生收入。
- Zoci此前已获SCLC孤儿药资格、epNEC快速通道和EMA相关孤儿药资格，本次NEC孤儿药认定更多是临床开发路径增量确认。
- 量级上，Zoci仍处注册性研究推进阶段，当前无法从新增患者数、价格、渗透率和权益比例估算短期收入或利润增量。
主要风险
- 药物仍需完成注册性研究并取得正式批准，孤儿药资格不保证疗效、审批成功或商业化规模。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-03 · 影响 weakens
未发现该资格已经转化为上市批准、销售收入或可量化商业合同；监管资格仅降低研发成本并提供潜在获批后独占期。
检索:Zai Lab zoci orphan drug designation approval revenue commercialization risk 原文 ↗
工具调用 · 历史记录,结果未知(1 种)
- search_processed_events · 结果未知
原文全文
展开原文 · 1,870 字
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks
SHANGHAI & CAMBRIDGE, Mass. - Zai Lab Limited (NASDAQ:ZLAB; HKEX:9688) announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to zocilurtatug pelitecan for the treatment of neuroendocrine carcinomas, according to a press release statement.
Zocilurtatug pelitecan, formerly known as ZL-1310, is an investigational Delta-like ligand 3 antibody-drug conjugate. Neuroendocrine carcinomas are malignancies that frequently express DLL3, with no available targeted therapies or approved standard of care for previously treated patients.
The FDA previously granted Fast Track designation to zoci for extrapulmonary neuroendocrine carcinomas, as well as Fast Track designation and Orphan Drug Designation for small cell lung cancer. The European Medicines Agency has also granted Orphan Drug Designation to zoci for pulmonary neuroendocrine carcinomas.
The Orphan Drug Designation provides eligibility for development incentives, including a waiver of the Prescription Drug User Fee Act registration application fee, tax credits for certain clinical trials, and potential seven-year U.S. market exclusivity upon product approval.
Zai Lab stated it plans to conduct three registration-enabling studies across second- and third-line small cell lung cancer, first-line small cell lung cancer, and extrapulmonary neuroendocrine carcinomas by the end of 2026.
Zocilurtatug pelitecan targets Delta-like ligand 3, which is overexpressed in many neuroendocrine carcinomas. The company is a commercial-stage biopharmaceutical company based in China and the United States, focused on developing products in oncology, immunology, neuroscience, and infectious disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SHANGHAI & CAMBRIDGE, Mass. - Zai Lab Limited (NASDAQ:ZLAB; HKEX:9688) announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to zocilurtatug pelitecan for the treatment of neuroendocrine carcinomas, according to a press release statement.
Zocilurtatug pelitecan, formerly known as ZL-1310, is an investigational Delta-like ligand 3 antibody-drug conjugate. Neuroendocrine carcinomas are malignancies that frequently express DLL3, with no available targeted therapies or approved standard of care for previously treated patients.
The FDA previously granted Fast Track designation to zoci for extrapulmonary neuroendocrine carcinomas, as well as Fast Track designation and Orphan Drug Designation for small cell lung cancer. The European Medicines Agency has also granted Orphan Drug Designation to zoci for pulmonary neuroendocrine carcinomas.
The Orphan Drug Designation provides eligibility for development incentives, including a waiver of the Prescription Drug User Fee Act registration application fee, tax credits for certain clinical trials, and potential seven-year U.S. market exclusivity upon product approval.
Zai Lab stated it plans to conduct three registration-enabling studies across second- and third-line small cell lung cancer, first-line small cell lung cancer, and extrapulmonary neuroendocrine carcinomas by the end of 2026.
Zocilurtatug pelitecan targets Delta-like ligand 3, which is overexpressed in many neuroendocrine carcinomas. The company is a commercial-stage biopharmaceutical company based in China and the United States, focused on developing products in oncology, immunology, neuroscience, and infectious disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。